Sign up


Match Document Document Title
8318173 Chimeric vaccines  
The invention provides chimeric proteins and nucleic acids encoding these which can be used to generate vaccines against selected antigens. In one aspect, a chimeric protein comprises an antigen...
8313748 Fusion protein vaccine  
The present invention relates to the fields of microbiology and vaccine technology, and concerns the development of a vaccine capable of conferring immunity to group B Streptococcus infections....
8309096 Fusion protein  
Fusion proteins comprising an antigen derived from NY-ESO-1 linked to an antigen derived from LAGE-1, which may further comprise carriers, fusion partners, or the like, are provided. Methods for...
8303962 Antibacterial and antifungal peptides  
This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various...
8303963 Methylated heparin-binding hemagglutinin recombinant mycobacterial antigen, preparation method and immunogenic compositions comprising same  
The invention concerns a methylated immunogenic recombinant peptide sequence comprising mycobacterial heparin-binding hemagglutinin. The invention also concerns chemical and enzymatic methods for...
8298551 Streptococcus pyogenes antigens and corresponding DNA fragments  
The present invention relates to antigens, more particularly antigens of Streptococcus pyogenes (also called group A Streptococcus (GAS)) bacterial pathogen which are useful as vaccine component...
8298547 IgE CH3 peptide vaccine  
The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier for the prevention, treatment or alleviation of...
8298545 Anti-autoimmune antibodies for treatment of pemphigus  
This invention relates to compositions and methods for the use of anti-autoimmune reagents that specifically bind to anti-desmoglein antibodies, which are responsible for both pemphigus vulgaris...
8298544 CEACAM based antibacterial agents  
Prophylactic and/or therapeutic antipathogen agents are provided that disrupt or prevent the formation of at least one homotypic and/or heterotypic protein-protein interaction that has at least one...
8298546 Isolation and purification of P. falciparum merozoite protein-142 vaccine  
In this application is the expression and purification of a recombinant Plasmodium falciparum (3D7) MSP-142. The method of the present invention produces a highly purified protein which retains...
8298552 Attenuated Mycoplasma gallisepticum strains  
The present invention provides live, attenuated Mycoplasma gallisepticum bacteria that exhibit reduced expression of a protein identified as MGA_0621. In certain embodiments, the attenuated...
8293250 Tuberculosis vaccines comprising antigens expressed during the latent infection phase  
The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M....
8293243 Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent  
The present invention relates to methods of treating mammals affected by, for example, a hyperproliferative disease such as cancer, by administering a tumor-targeted superantigen and a...
8293244 Phosphotriesterase from agrobacterium radiobacter p230  
The present invention provides enzymes capable of hydrolysing organophosphate (OP) molecules. In particular, the invention provides a phosphotriesterase enzyme identified from an Agrobacterium...
8293247 Modified influenza virus for monitoring and improving vaccine efficiency  
The immunogenicity of the influenza virus hemagglutinin (HA) molecule may be increased by substitutions of amino acids in the HA sequence. The substitution of specific HA residues, such as...
8288352 Auristatins having an aminobenzoic acid unit at the N terminus  
Auristatin-type peptides are disclosed which are highly cytotoxic, synthetically accessible, and can be conjugated to antibodies and other ligands.
8288509 Therapeutic agent for infections, and treatment method using the same  
(Problems) To provide a therapeutic agent for infections comprising granulysin as an active ingredient which has little side effect and no cytotoxicity and to which bacteria can hardly acquire...
8287876 Recombinant chimeric antigens for diagnosis and prevention of scrub typhus  
Recombinant chimeric antigens comprising unmodified and modified reactive polypeptide fragments of expressed product of the recombinant 56 kDa proteins of multiple strain of scrub typhus, such as...
8287860 Immunogen and antivenom against violin spider venom  
The invention relates to the isolation, characterization and expression of DNA fragments encoding sphingomyelinases D from three species of Loxosceles genus spiders, namely L. boneti, L reclusa and...
8287875 Nucleic acids encoding a house dust mite allergen, Der p III, and uses therefor  
Isolated nucleic acids encoding an allergen of Dermatophagoides pteronyssinus, Der p III, are disclosed. A cDNA encoding a peptide having a Der p III activity and a predicted molecular weight of...
8283440 Snapin and methods for regulation of microtubule assembly and dendrite growth and branching  
Fragments of snapin important for interaction with cypin and thus regulating microtubule assembly are provided. Also provided are methods of use of said fragments and kits to facilitate said methods.
8283458 VMP-like sequences of pathogenic Borrelia species and strains  
The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic Borrelia, the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino...
8283315 Inhibition of tumour growth  
The present invention provides a cytotoxic 7 to 25 mer peptide with three or more cationic residues which has one or more non-genetic bulky and lipophilic amino acids, as well as esters, amides,...
8283447 Immunosuppressive polypeptides and nucleic acids  
The invention provides immunosuppressive polypeptides and nucleic acids encoding such polypeptides. In one aspect, the invention provides mutant CTLA-4 polypeptides and nucleic acids encoding...
8282942 Toxoplasma gondii vaccines and uses thereof  
The present invention provides attenuated Toxoplasma gondii knockout mutants of the de novo pyrimidine synthesis pathway and use of the same in vaccines and methods of providing an immune response...
8282931 Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof  
Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such...
8282932 Split-core-particles for the presentation of foreign molecules, especially for vaccine applications, and method for their production  
Disclosed are split-core carrier substance which, as separate polypeptide, have the core N domain and the core C domain of the core protein of a hepatitis B virus and at least one foreign molecule...
8278412 Polypeptide, nucleic acid molecule encoding it and their uses  
A polypeptide containing epitope of the amino acid sequence shown in SEQ ID NO:3 is provided, which is selected from the amino acid sequence of SEQ ID NO:3 and amino acids at 16-32 positions, amino...
8277814 Avian Astrovirus  
The present invention relates to the fields of veterinary virology and immunology. In particular the invention relates to a novel avian Astrovirus; to antibodies or fragments thereof against the...
8277817 PEGylation by the dock and lock (DNL) technique  
The present invention concerns methods and compositions for forming PEGylated complexes of defined stoichiometry and structure. In preferred embodiments, the PEGylated complex is formed using...
8277820 Process for preparing variant of Erysipelothrix rhusiopathiae surface protective antigen in E. coli  
A variant of Erysipelothrix rhusiopathiae surface protective antigen SpaA protein or of a shortened form of SpaA (ΔSpaA) in which a portion of SpaA protein is deleted for protection from ...
8277813 Identification and molecular characterisation of proteins, expressed in the Ixodes ricinus salivary glands  
The invention relates to a new polynucleotide which encodes a polypeptide expressed in the salivary glands of ticks, more particularly the Ixodes ricinus arthropod tick, during the slow-feeding...
8277778 Vaccine adjuvants  
The invention relates to a novel adjuvant Mycobacterium w and or its constituents and adjuvant containing composition, which contains antigen(s) with pharmaceutical acceptable carrier and its uses....
8277816 Bacillus anthracis antigens, vaccine compositions, and related methods  
The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by Bacillus...
8273865 Multivalent clostridial toxins  
The present invention is directed to multivalent Clostridial toxin comprising more than one binding domain directed to a cell surface molecule of a target cell. Such modified toxins are useful as...
8268322 Polypeptide specifically binding to vascular endothelial growth factor, fusion protein including polypeptide, and methods therefor  
A polypeptide inhibiting binding between a vascular endothelial growth factor and a vascular endothelial growth factor receptor, a fusion protein including the same, and a method of preparing the...
8268783 Antidotes for factor Xa inhibitors and methods of using the same  
The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby...
8268321 Antigen-drug vehicle enabling transmucosal and transdermal administration, and method of inducing mucosal immunity and mucosal vaccine and DDS using the same  
Disclosed are an antigen-drug vehicle (AD vehicle) exerting a function of inducing the preferential and selective production of an antigen-specific secretory IgA antibody, local immunity or mucosal...
8268587 Immunosuppressive polypeptides and nucleic acids  
The invention provides immunosuppressive polypeptides and nucleic acids encoding such polypeptides. In one aspect, the invention provides mutant CTLA-4 polypeptides and nucleic acids encoding...
8263088 Clostridial toxin NetB  
The present invention relates to a polypeptide based toxin that originates from Clostridium perfringens. The invention further relates to immunogenic compositions comprising the toxin and methods...
8263089 Compounds and methods for treatment and diagnosis of chlamydial infection  
Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia...
8263081 Antibody-light fusion products for cancer therapeutics  
Antibody-LIGHT fusion products or conjugates stimulate immunity against tumors and eradicate metastases. Tumor-specific antibodies coupled with LIGHT effectively target metastatic tumors and...
8258257 Claudin-4 binding peptides, compositions and methods of use  
The disclosure provides methods and compositions useful for treating claudin-4 associated disorders including cell proliferative disorders. The disclosure also provide claudin-family binding...
8257714 Compositions and methods for immunotherapy of cancer and infectious diseases  
The present invention provides compositions and methods for the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases, for stimulating an immune response in...
8257713 Vaccine  
The present invention is concerned with the development of a vaccine against Aeromonas hydrophila for use especially in fish. The invention provides an immunogenic S-layer protein of approximately...
8257711 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides  
The present invention provides immunogenic peptides comprising the amino acid sequence of SEQ ID NO: 1, 2, 13, 32, and peptides comprising the above-mentioned amino acid sequences in which 1, 2, or...
8252545 Peptides of a melanoma antigen and their use in diagnostic, prophylactic, and therapeutic methods  
Immunogenic peptides of a melanoma antigen recognized by T cells, designated gp100, bioassays using the peptides to diagnose, assess or prognose a mammal afflicted with cancer, more specifically...
8252293 Binding domain of Plasmodium reticulocyte binding proteins  
The present invention provides isolated polynucleotides, polypeptides, antibodies and/or vaccines for the prevention and/or treatment of malaria caused by Plasmodium falciparum and/or Plasmodium...
8246960 Methods and compositions for generating bioactive assemblies of increased complexity and uses  
The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In...
8241608 Treating allergy with detoxified E. coli heat-labile enterotoxin  
A method for treating allergy with a pharmaceutical composition containing a detoxified E. coli heat-labile enterotoxin, and, optionally, an allergen.